C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19

Thursday, January 28, 2021

AbCellera announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19. Bamlanivimab is currently a component in all Lilly’s antibody-based COVID-19 therapies, which include bamlanivimab alone, and bamlanivimab and etesevimab together. Lilly will expand the ongoing BLAZE-4 trials to evaluate bamlanivimab together with VIR-7831.

Bamlanivimab is a human antibody that reduces the risk of contracting COVID-19 by up to 80% in people exposed to the virus, prevents COVID-19 related deaths, and reduces hospitalizations by 70%-80% in patients recently diagnosed with mild to moderate COVID-19. Bamlanivimab, which was discovered by AbCellera in March 2020 and reached human clinical trials 90 days later, was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) in November 2020.

“To date, more than 100,000 patients have received bamlanivimab, and the data from clinical trials show its use saves lives and prevents hospitalizations,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “Bamlanivimab alone remains an important antibody therapy, and we are pleased it will be evaluated with VIR-7831 to potentially expand the impact of antibody therapies on viral variants.”

To date, bamlanivimab 700 mg has been authorized in the United States, Canada, Germany, Israel, Hungary, United Arab Emirates, Kuwait, Saudia Arabia, and Panama to treat mild to moderate COVID-19 in high-risk patients.

Latest Issue
Get instant
access to our latest e-book
Saving Money, Saving Time In Pharma Operations Catalent  Asia-Pacific Clinical Supply Solutions SGS - Health Science Horizon - CHOSOURCE advances biotherapeutic production MasterControl - The Never-Normal Future of Manufacturing Medical Fair Thailand 2022 Meco - 90 years